Abstract
Hemodynamic derangements are defining features of cardiogenic shock. Randomized clinical trials have examined the efficacy of various therapeutic interventions, from percutaneous coronary intervention to inotropes and mechanical circulatory support (MCS). However, hemodynamic management in cardiogenic shock has not been well-studied. This State-of-the-Art review will provide a framework for hemodynamic management in cardiogenic shock, including a description of the 4 therapeutic phases from initial 'Rescue' to 'Optimization', 'Stabilization' and 'de-Escalation or Exit therapy' (R-O-S-E), phenotyping and phenotype-guided tailoring of pharmacological and MCS support, to achieve hemodynamic and therapeutic goals. Finally, the premises that form the basis for clinical management and the hypotheses for randomized controlled trials will be discussed, with a view to the future direction of cardiogenic shock.
Original language | English |
---|---|
Pages (from-to) | 1059-1073 |
Journal | The Journal of Heart and Lung Transplantation |
Volume | 43 |
Issue number | 7 |
Early online date | 20 Mar 2024 |
DOIs | |
Publication status | Published - 1 Jul 2024 |
Bibliographical note
Copyright © 2024 The Authors.Keywords
- cardiogenic shock
- mechanical circulatory support
- hemodynamics
- inotropes
- heart transplantation
- left ventricular assist devices